T H 17 cells are a subset of interleukin-17 (IL-17)-secreting Thelper (T H ) cells implicated in the pathogenesis of multiple sclerosis (MS), rheumatoid arthritis, juvenile idiopathic arthritis (JIA), and psoriasis 1,2 , whose differentiation is regulated by the transcription factor RAR-related orphan nuclear receptor gamma (RORγt) 3 . Initially, T H 17 cells were considered a uniformly pro-inflammatory population driven by IL-23 and expressed a unique pattern of pro-inflammatory cytokines different from T H 1 and T H 2 cells [4] [5] [6] . Subsequent studies showed the function of T H against bacterial and fungal pathogens [7] [8] [9] [10] . T H 17 cells can be induced to produce T H 1 and T H 2 cytokines 11 and not all T H 17 cells are pathogenic. Murine T H 17 cells are pathogenic or nonpathogenic based on their ability to induce experimental autoimmune encephalomyelitis (EAE) 12 ; pathogenic T H 17 cells express higher levels of IFN-γ while non-pathogenic T H 17 cells produce IL-10 with IL-17 13 .
As in mice, human T H 17 cells can also co-produce IFN-γ or IL-10. IL-10-producing T H 17 cells are induced in response to Staphylococcus aureus, whereas T H 17 cells induced by Candida albicans produce IL-17 and IFN-γ. Both types of T H 17 cells are enriched in a subset of human memory CD45RA -CD4 + T H cells expressing the chemokine receptors CCR6 and CCR4, while IFN-γ-secreting T H 17 (T H 1/17) cells may additionally express CXCR3 9, 14 . A deficiency in IL-17 or the T H 17 pathway compromises host defenses against S. aureus and C. albicans, and reduces the frequency of circulating CCR6 + memory CD4 + T H cells 15, 16 . Thus both IFN-γ and IL-10-producing T H 17 cells may be protective during infection.
IFN-γ and IL-10-producing T H 17 cells are considered proinflammatory and anti-inflammatory, respectively, and have opposite functions in autoimmunity 17, 18 . Studies of T-cell libraries from patients with MS showed that CCR6 + myelinreactive T cells exhibit enhanced production of IFN-γ, IL-17, and GM-CSF and reduced production of IL-10, when compared with those from healthy individuals 19 . In JIA, IFN-γ-secreting T H 1/17 cells are highly enriched in the synovial fluid (SF) of inflamed joints 20 . The inflammatory environment in diseased joints can induce IFN-γ-negative T H 17 cells to co-produce IFN-γ, implicating plasticity of T H 17 cells 21 . The proportions of T H 1/17-enriched CD4 + CD161 + T cells in the SF of affected joints correlate with the erythrocyte sedimentation rate and serum levels of C-reactive protein, suggesting these cells function in disease pathogenicity 20 . These and other reports of elevated numbers of T H 1/17 cells in inflamed tissues in human autoimmune diseases [21] [22] [23] associate T H 1/17 cells with human autoimmune diseases.
The complexity of T H 17 function is further manifested in therapeutic studies. Although anti-IL-17 therapy benefits psoriasis, blocking the IL-17 pathway in Crohn's disease is either ineffective or exacerbates diseases [24] [25] [26] . Similarly, in the CD45RB hi adoptive transfer mouse model of experimental colitis, a deficiency of IL-17 production or IL-17R expression in transferred CD45RB hi CD4 T cells results in accelerated disease 27 . The protective function of IL-17 in these studies may be due to the fact that T H 17 cells that line the gut mucosa prevent invasion of the gut microbiome and promote intestinal homeostasis 28 . In tumors, T H 17 cells are reported to have both beneficial [29] [30] [31] and detrimental effects 32 both in animal models and human disease. Hence, the function of T H 17 cells in diverse immune responses is complex.
We previously reported that murine T H 17 cells can be differentiated into pathogenic vs. non-pathogenic subsets, as well as characterized the molecular signature of murine pathogenic T H 17 cells through global gene expression analysis 12 
Results

Transcriptionally distinct T H 17 subsets in peripheral blood.
We first performed intracellular cytokine staining of blood CD4 + T cells and identified distinct populations of IFN-γ co-producing T H 17 cells, but no IL-10 co-producing T H 17 cells (Fig. 1a ; Supplementary Fig. 1 ). It is known that IFN-γ + T H 17 cells are increased in inflamed tissues in human autoimmune diseases [21] [22] [23] , and are also present in the blood of healthy individuals, whereas IL-10 + T H 17 cells are barely detected 14 (Fig. 1c) , thus demonstrating that we isolated pure populations of T H 1/17, T H 17, and T H 1 cells. IL10 gene expression was detected in both T H 17 and T H 1/17 cells (Fig. 1d) .
For the 20 CD4 + T-cell subset samples from the five healthy individuals we analyzed, 362 of the 418 genes demonstrated unbiased variation across the population, defined as an unsupervised expression difference (difference between maximum and minimum relative gene expression values, not taking into account information about the subset classes) ≥5 across all samples, and these genes were selected for further study. Hierarchical clustering of gene expression profiles of the 20 individual samples from the CD4 + subpopulations in the context of these 362 unsupervised varying genes properly segregated the T H 1/17, T H 17, T H 1, and DN cells into four different clusters, revealing their distinct transcriptional features (Fig. 1e) . The ingroup Pearson correlation values for these gene expression profiles were high for all four CD4 + T-cell subsets and ranged from 0.95 ± 0.06 for DN cells to 0.98 ± 0.02 for T H 1 cells. Pearson correlation values for the gene expression profiles of T H 1/17 vs. T H 17 and T H 1/17 vs. T H 1 were 0.83 ± 0.05 and 0.78 ± 0.06, respectively, whereas the correlation coefficient for T H 17 vs. T H 1 was only 0.43 ± 0.06 (Fig. 1f) , which were consistent with the degree of similarities observed among the cell subsets in the hierarchical clustering analysis (Fig. 1e) . Principal component analysis (PCA) showed that DN cells were clearly distinct from the other three subsets, whereas T H 1/17 cells lay in between T H 17 and T H 1 cells (Fig. 1g) Fig. 2b, c) . The "leading edge" subset of genes is defined as genes that drive the enrichment scores, thus the genes that appear in the top of the ranked list of genes at, or before, the point where the running sum reaches the maximum deviation from zero. The "leading edge" subset can be interpreted as the core subset of a gene set that accounts for the enrichment signal 34 . Genes upregulated in human T H 17 vs. T H 1/17 cells were also enriched in mouse non-pathogenic T H 17 cells vs. pathogenic T H 17 cells in both comparison scenarios, with seven identical "leading edge" genes (Kolmogorov-Smirnov test p = 0.0007; FDR q = 0.001 for Scenario I; Kolmogorov-Smirnov test p = 0.004; FDR q = 0.004 for Scenario II) (lower panels of Fig. 2b, c) Among the 27 signature genes identified in both comparison scenarios, 13 had an absolute fold change >1.5 for T H 1/17 vs. T H 17 cells, which were selected as the robust predicted pathogenic signature (PreP-Signature) of T H 1/17 cells for later analyses (Fig. 2d) . The upregulated robust PreP-Signature genes with pro-inflammatory/pathogenic potential can be grouped into chemokines and cytokines (CCL3, CCL4, CCL5, CSF2, IFNG, and IL3), chemokine and cytokine receptors (CXCR3 and IL23R), cytokine responding genes (EPSTI1), effector proteins (GZMB), and signaling molecules (RGS2). The downregulated genes are the chemokine receptor (CCR6) and the transcription factor (STAT1).
We also investigated genes not shared between human and mouse pathogenic/non-pathogenic Th17 cells to identify other potentially relevant genes to test in human conditions. We identified 33 non-shared genes including 19 that were upregulated and 14 that were downregulated (Supplementary Data 4).
Human ex vivo T H 17 subsets vs. T H 17 clones.
IL-10 has a pivotal role in regulation of both innate and adaptive immunity 35 and murine TGF-β1/IL-6-induced non-pathogenic T H 17 cells produce IL-10 13 . Human IL-10 + T H 17 cells are a potential counterpart of mouse non-pathogenic T H 17 cells. However, IL-10-secreting T H 17 cells cannot be directly isolated from human blood for nCounter gene expression analysis because few or no T H 17 cells produce IL-10 after PMA/ionomycin stimulation (Fig. 1a) . This is likely due to the delayed production of IL-10 after stimulation. Nonetheless, for established human T H 17 clones, IL-10 + T H 17 clones can be identified by IL-10 intracellular staining 5 days after T-cell receptor activation 9 . Thus, we established CD4 + T cells clones from CCR6 + CCR4 + CXCR3 -memory CD4 + T cells ( Supplementary Fig. 3 ) that were enriched for T H 17 cells 14, 18 and screened for clones producing IL-17 with or without co-secretion of IL-10. qRT-PCR showed that IL-10 -T H 17 clones expressed high levels of IFNG, low levels of IL10, and high levels of IL23R, whereas IL-10 + T H 17 clones expressed minimal levels of IFNG and high levels of IL10 (Fig. 3a) . To assess whether the gene expression profile of cloned T H 17 cells maintained their pro or anti-inflammatory features after long-term culture, we used the and mouse pathogenic T H 17 cells (Fig. 2b, c (Fig. 3c) , especially for activation of IL-1β signaling, which is critical to promote co-producing IFN-γ and to inhibit IL-10 production in T H 17 cells 9 . These results demonstrate the similarities between T H 1/17 vs. T H 17 cells and IL-10 -vs. IL-10 + T H 17 clones, and also indicate that IL-10 -and IL-10 + T H 17 clones maintained their pro-or anti-inflammatory characteristics after long-term culture. TGFβ1   CBLB  CCL4  CCL5  CSF2  CXCR3  EPSTI1  IFNG  IL2  IL22  IL23R  IL3  REL  RGS2  SLAMF1  STAT4  TBX21  TNFSF14   AHR  ANTXR2  CCR6  IFNGR2  IGSF3  NETO2  STAT1   CBLB  CCL3  CCL4  CCL5  CSF2  CXCR3  EGR3  EPSTI1  GZMB  IFNG  IL2  IL22  IL23R  IL3  REL  RGS2  SLAMF1  STAT4  TBX21   AHR  ANTXR2  CCR6  IFNGR2  IGSF3  NETO2  STAT1   TGFβ3 -1 0 1 (Fig. 5a ). The percentage of T H 1/17 in total T H 17 cells was also similar (Fig. 5b) . To assess purity of isolated cell subsets, we measured the expression of IL17 and IFNG by qPCR. We detected high levels of IL17 in T H 1/17 and T H 17 cells but not in DN cells (Supplementary Fig. 4a ), and high levels of IFNG in T H 1/17 cells but not in T H 17 and DN cells ( Supplementary  Fig. 4b ), demonstrating that the isolated populations were of high purity. In both groups, IL17 expression was higher in T H 17 vs. T H 1/17 cells ( Supplementary Fig. 4a ), whereas IL17 expression was similar for T H 1/17 and T H 17 cells (Fig. 5c ). To validate the 13 robust PreP-Signature genes identified via the nCounter analysis, we measured their expression in T H 1/17 and T H 17 cells in healthy controls by qPCR (Fig. 5d, left) . For the 11 genes upregulated in T H 1/17 cells, 9 were confirmed; the 2 downregulated genes were not validated. In MS, the nine validated genes displayed the similar upregulated expression pattern (Fig. 5d, right) . Thus, the transcriptional regulation of the nine validated robust PrePSignature genes of T H 1/17 cells was tightly associated with IFN-γ secretion in both controls and MS. These results indicate that studying frequency or number of IFN-γ-secreting T H 17 cells may not identify important biological differences.
We investigated differences between MS and control using the robust PreP signature genes we identified above. We first measured the expression of the 13 robust PreP-Signature genes in T H 1/17 cells in MS and found elevated expression of CXCR3 and reduced expression of IFNG, CCL3, CLL4, and GZMB (Fig. 6a) . In T H 17 cells, GZMB showed reduced expression in MS (Fig. 6b) . No difference was observed between MS and controls in T H 1 cells (Supplementary Fig. 5 ). Thus, the altered expression of these five PreP-Signature genes are specific for T H 1/17 and T H 17 subsets, but not for T H 1 cells. We then measured the expression of TBX21 and IL10, since we found downregulation of TBX21 and upregulation of IL10 in IL-10 + T H 17 clones (Fig. 3a, d) . We found TBX21 expression elevated in T H 1/17 relative to T H 17 cells in MS and controls (Fig. 6c, upper panel) , with no difference in IL10 (Fig. 6d, upper panel) . However, when we compared T H 1/17 and T H 17 cells between MS and controls, IL10 was reduced in T H 1/17 and T H 17 cells in patients (Fig. 6d, lower panel) , though no difference was detected with TBX21 expression (Fig. 6c, lower  panel) . The predicted upstream transcription factor STAT3 was elevated in the DN cells in MS (Fig. 6e, upper panel) , while the expression of its antagonistic transcription factor STAT5A 38-40 was reduced (Fig. 6e, lower panel) . CBLB  CCL5  CD160  CDC37  CXCR3  DPP4  FUS  IL12RB2  IL23R  IRF1  LYAR  NFAT5  NOP16  REL  TBX21  TNFSF14  UCHL3   ANTXR2  ETS1  IFNGR2  IKZF3  RNF125  SLC44A1   CBLB  CCL5  CXCR3  DPP4  FUS  IL12RB2  IL23R  IRF1  LYAR  NOLC1  NOP16  REL  TBX21  UBXN8   PIK3lP1   ANTXR2  ETS1  IFNGR2  IKZF3   RNF125 which is consistent with our observation of their expression in DN cells in MS. We then investigated whether the PreP-Signature genes, which had altered expression in MS, were linked to disease activity in MS. Disease activity was defined as a gadolinium-enhancing lesion on magnetic resonance imaging (MRI) or disease relapse within 6 months to the time of blood sampling. All patients were untreated at the time of blood sampling. From (Fig. 7) . Given the facilitating role of STAT3 in T H 17 differentiation and the anti-inflammatory function of IL-10, these results together with the altered expression of CXCR3, IFNG, CCL3, CLL4, GZMB, IL10, STAT3, and STAT5A in MS (Fig. 6) [41] [42] [43] [44] . Given that IL-10 is a potent anti-inflammatory cytokine, this combination may facilitate migration of more proinflammatory CXCR3 hi IL-10 low T H 1/17 cells to the inflamed CNS. However, it is unexpected to observe reduced expression of signature genes IFNG, CCL3, CLL4, and GZMB in T H 1/17 cells in MS vs. healthy controls, especially the reduced expression of IFNG. Natalizumab, a humanized monoclonal antibody targeting α4 integrin used in the treatment of MS, functions by preventing immune cells from crossing the blood-brain barrier 45 . A study has shown that both natalizumab treated and untreated patients during relapse have lower frequencies of T H 17 cells in peripheral blood compared to stable patients. Moreover, T H 17 cells become almost undetectable in patients with breakthrough disease that occurs following natalizumab withdrawal 46 . Thus, one explanation for reduced expression of IFNG, CCL3, CLL4, and GZMB in T H 1/17 cells in MS could be that migration of cells to the CNS removes CXCR3 high, active T H 1/17 cells from the blood. Another possibility may be that expression of IFN-γ ensures high expression of CXCR3, which is critical for cells to migrate to inflamed CNS, and reduced IFN-γ may indicate the further enhancement of the pathogenicity of IL-10 lo T H 17 cells in MS. 47 . Although counter-intuitive, the potent pro-inflammatory T H 1 cytokine IFN-γ is protective during EAE induction [48] [49] [50] . It suppresses EAE induction by inhibiting generation of T H 17 cells 51 , converting CD4 + CD25 -T cells to CD4 + Tregs 52 and limiting myelin lipid peroxidation in CNS 53 . IFN-γ is dispensable for generation of pathogenic T H 17 cells, however, T-bet the transcription factor for T H 1 was initially considered essential due to the high resistance of Tbet −/− mice to EAE 54, 55 . Later studies show that T-bet is essential for T H 1 but not T H 17-mediated EAE 56, 57 . Studies in Tbet −/− mice have shown that reduced IFN-γ in T H 17 cells does not affect their pathogenicity though the conversion of T H 17 cells to T H 1/17 cells as well as T H 1-like IFN-γ + ex-T H 17 cells is prevented 56, 58, 59 .
IFN-γ-stimulation is required for CXCR3 induction on T cells upon T-cell receptor stimulation
Interrogating the PreP-Signatures for the identification of upstream regulators and transcription factors 36, 37 , we identified STAT3 as the top predicted upstream transcription factor from Leveraging comparative transcriptomic approaches, we integrated gene expression profiles derived from human and mouse T H 17 cells to identify pathogenicity-associated signature (PrePSignature) genes that are shared by human pro-inflammatory T H 17 cells and mouse pathogenic T H 17 cells, and to predict the upstream regulators or transcription factors that may be critical for the differentiation of human pro-inflammatory T H 17 cells. These comparative transcriptomic analyses allowed us to identify altered gene expression associated with T H 17 subsets and their differentiation in subjects with MS and to identify associations of the expression of STAT3 in DN cells and IL10 in T H 17 cells that are dependent on MS disease activity. Of note, we used a nCounter codeset with a limited set of pre-selected 418 genes, which may miss other disease related, highly discriminant genes in humans. Thus, follow-up studies, such as RNA-sequencing analysis on T H 17 and T H 1/17 subsets isolated from MS patients, may help to identify more disease-related genes. 
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Up-regulated genes Down-regulated genes (Fig. 2b, c) and T H 17 clones (Fig. 3d, e) , respectively. Genes with supervised absolute fold change >1. MS patients were untreated for a minimum of 6 months before sampling. Disease activity was identified as a gadolinium-enhancing lesion on MRI or disease relapse within 6 months of sampling. Age-and sex-matched healthy donors did not have history of autoimmune diseases or malignancies and no acute or chronic infections. The samples from healthy donors for nCounter gene expression analysis were fresh blood samples. The MS samples and age-and sex-matched healthy control samples were frozen peripheral blood mononuclear cells (PBMCs).
Intracellular cytokine staining. For intracellular cytokine staining for PBMC or CD4 + T cells, assays were carried out with staining buffers and antibodies from BD Biosciences. Briefly, cells were seeded into a 96-well plate (up to 1 × 10 6 cell per well) and stimulated with PMA (100 ng/ml) and ionomycin (1 μg/ml) in the presence of GolgiStop for 4 h. After stimulation, cells were fixed with BD Cytofix fixation buffer and washed with BD Perm/Wash buffer. Cells in each well were equally divided into two wells, with one for intracellular cytokine staining and the other for isotype control staining. The following fluorophore-conjugated antibodies from BD Biosciences were used for staining analysis or as isotype controls: anti- Data analysis. nCounter gene expression data were normalized for code count using the geometric mean, for background using the mean, and for sample content using the geometric mean of housekeeping genes (isolated human CD4 + T-cell subsets: B2M, RPL3, and beta actin; human T H 17 clones: B2M, GAPDH, and beta actin) with the R 3.2.0. NanoStringNorm package. Mouse gene expression data were downloaded from GEO (GSE39820) and normalized using RMA 62 and ComBat 63 in GenePattern (http://www.broadinstitute.org/cancer/software/ genepattern/) as previously published 12 . Genes for which multiple probes were measured on the mouse microarray were collapsed to unique genes by selecting the probe with the highest average expression across all samples. Hierarchical clustering of the human samples and of the pairwise Pearson linear correlations were done based on the 362 genes that varied across the population in an unbiased manner (unsupervised expression difference (Δ = maximum expression valueminimum expression value)≥5, defined as the difference between maximum and minimum relative gene expression values across the population without considering the subset classes) using Pearson linear correlation and average linkage in GENE-E. PCA of the isolated human CD4 + T-cell subsets was done in R (prcomp) based on the same 362 genes. We selected differentially expressed genes between T H 1/17 and T H 17 cells using the two tailed, paired Student's t test followed by supervised filtering for expression differences between mean T H 1/17 and mean T H 17 (Δ = MEAN TH1/17 −MEAN TH17 )>20 for robustness. The same approach was used to select differentially expressed genes between IL-10 − and IL-10 + T H 17 clones. GSEA was done in GenePattern using default settings (weighted scoring scheme, Signal2Noise metric, 1000 permutations) 34, 64, 65 to test the enrichment of human signatures in the mouse expression profiles. Gene set overlap statistic analysis was done using the hypergeometric test in R (phyper, with N equal to the number of genes measured on the NanoString CodeSet). Storey's q-value is used to control the FDR. Visualization of the gene expression heatmaps was done in GENE-E [http://www.broadinstitute.org/cancer/software/GENE-E/]. Il23r was not included in our microarray chip for mouse T H 17 cell analysis, but we found upregulation of Il23r in murine pathogenic T H 17 cells by qPCR 12 . Thus, we included Il23r in the murine gene expression profiles. The IPA upstream regulator analysis was performed for the differentially expressed genes (using corresponding fold changes and p-values) to identify key upstream regulatory molecules.
Upstream regulators with z-scores >2 and z-scores <−2 represent activator and inhibitor mechanisms, respectively. The Enrichr ChEA2016 database and analytic tools were used to predict key upstream transcription factors 36, 37 . The mRNA levels of signature genes with altered expression in MS (Fig. 6 ) were compared between active and stable patients. Signature gene expression in a T H 1/17 (active, n = 8; stable, n = 7), b T H 17 (active, n = 12; stable, n = 6), and c DN cells (active, n = 12; stable, n = 7) (Welch's t test, mean ± s.d.)
differential gene expression between healthy controls and MS patients on a specific T H subset. Two sided p-values of <0.05 were considered statistically significant.
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